InVivo Therapeutics Reports $3M Net Income in 3Q

Written by Laura Dyrda | November 18, 2011 | Print  |
InVivo Therapeutics reported net income of $3 million for the third quarter of 2011, according to a company news release. Research expenses for the third quarter were reported as more than $1 million, significantly higher than the $325,000 reported during the third quarter of 2010. General and administrative expense also more than doubled from the third quarter of 2010 to include nearly $1.2 million in the third quarter of 2011.

During the third quarter, the company submitted an IDE and are awaiting FDA clearance to begin a human clinical study with the company's proprietary biopolymer scaffolding device for acute spinal cord injury. The company also appointed a medical director and chief scientific officer and expanded the neuroscience team to include a laboratory director and research and development manager.

Related Articles on Orthopedic Device Companies:

Alphatec Spine Names Frances Harrison to Vice President Position

TranS1 Launches Lateral Access Spinal System

K2M Debuts New Cervical Plate System With Blue Ridge Technology

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months